

# **SUPPLEMENTAL MATERIAL**

**Table S1. Representation in Clinical Studies on Cardioprotective Interventions.**

| Author, Year, Name of Study             | Study Type | Country | Malignancy  | Main Treatment             | Cardio-protective Intervention | CV Risk Factors* | Demographics Sex/Gender | Demographics Race/Ethnicity    | Inclusion of Socioeconomic Variables |
|---|------------|---------|---|----------------------------|--------------------------------|------------------|-------------------------|--------------------------------|--------------------------------------|
| <b>Lifestyle</b>                        |            |         |   |                            |                                |                  |                         |                                |                                      |
| <b>Kirkham, 2018<sup>86</sup></b>       | RCT        | Canada  | Breast cancer   | Doxorubicin                | Vigorous intensity exercise    | Yes              | N/A                     | 75% white, 21% Asian, 4% other | Education level, marital status      |
| <b>Neurohormonal agents<sup>†</sup></b> |            |         |   |                            |                                |                  |                         |                                |                                      |
| <b>Nakamae, 2005<sup>87</sup></b>       | RCT        | Japan   | NHL   | CHOP                       | Valsartan                      | No               | 53% female              | No information                 | None                                 |
| <b>Cardinale, 2006<sup>88</sup></b>     | RCT        | Italy   | Breast cancer, HL, NHL, myeloma, AML, Ewing's sarcoma | Chemo-therapy <sup>‡</sup> | Enalapril                      | Yes              | 63% female              | No information                 | None                                 |

|   |        |        |   |  |                                       |     |            |                |      |
|---|--------|--------|---|--|---------------------------------------|-----|------------|----------------|------|
| <b>Cardinale, 2010<sup>89</sup></b>         | Cohort | Italy  | Breast cancer, HL, NHL, leukemia, other | Anthracycline-based therapy                  | Enalapril or enalapril and carvedilol | Yes | 74% female | No information | None |
| <b>Georgakopoulos, 2010<sup>90</sup></b>    | RCT    | Greece | HL and NHL                              | Doxorubicin-based therapy                    | Enalapril or metoprolol               | Yes | 48% female | No information | None |
| <b>Bosch, 2013<sup>91</sup></b><br>OVERCOME | RCT    | Spain  | Leukemia, HL, NHL, multiple myeloma     | Chemo-therapy <sup>‡</sup> and HSCT          | Enalapril and carvedilol              | Yes | 43% female | No information | None |
| <b>Kaya, 2013<sup>92</sup></b>              | RCT    | Turkey | Breast cancer                           | Anthracycline-based therapy                  | Nebivolol                             | Yes | N/A        | No information | None |
| <b>Gulati, 2016<sup>93</sup></b><br>PRADA   | RCT    | Norway | Breast cancer                           | 5-fluorouracil, epirubicin, cyclophosphamide | Candesartan or metoprolol succinate   | Yes | N/A        | No information | None |



|   |     |                  |   |                                 |                             |     |               |                                     |      |
|---|-----|------------------|---|---------------------------------|-----------------------------|-----|---------------|-------------------------------------|------|
|   |     |                  | breast<br>cancer  | mide,<br>paclitaxel             |                             |     |               |                                     |      |
| <b>Cardinale,<br/>2018<sup>98</sup></b> | RCT | Italy            | Breast<br>cancer,<br>acute<br>leukemia,<br>HL, NHL,<br>and<br>sarcoma | Anthracycline-<br>based therapy | Enalapril                   | Yes | 88%<br>female | No<br>information                   | None |
| <b>Guglin,<br/>2019<sup>99</sup></b>    | RCT | United<br>States | HER2<br>positive<br>breast<br>cancer                                  | Trastuzumab-<br>based therapy   | Lisinopril or<br>carvedilol | Yes | N/A           | 86% white,<br>7% Black,<br>6% other | None |
| <b>Statins</b>                          |     |                  |   |                                 |                             |     |               |                                     |      |
| <b>Acar, 2011<sup>100</sup></b>         | RCT | Turkey           | Leukemia,<br>NHL,   | Anthracycline-<br>based therapy | Atorvastatin                | No  | 58%<br>female | No<br>information                   | None |

---

multiple  
myeloma

---

|  |        |                  |                  |                                 |        |     |     |   |   |
|--|--------|------------------|------------------|---------------------------------|--------|-----|-----|---|---|
| <b>Seicean,<br/>2012<sup>101</sup></b> | Cohort | United<br>States | Breast<br>cancer | Anthracycline-<br>based therapy | Statin | Yes | N/A | 71% white<br>(no other<br>races<br>specified) | Education<br>level, family<br>income,<br>marital<br>status,<br>healthcare<br>access |
|--|--------|------------------|------------------|---------------------------------|--------|-----|-----|---|---|

|  |        |        |                                      |                               |        |     |     |                   |      |
|--|--------|--------|--------------------------------------|-------------------------------|--------|-----|-----|-------------------|------|
| <b>Calvillo-<br/>Argüelles,<br/>2019<sup>102</sup></b> | Cohort | Canada | HER2<br>positive<br>breast<br>cancer | Trastuzumab-<br>based therapy | Statin | Yes | N/A | No<br>information | None |
|--|--------|--------|--------------------------------------|-------------------------------|--------|-----|-----|-------------------|------|

---

**Dexrazoxane**

---

|                                       |     |                  |                  |                                 |             |     |     |                   |      |
|---------------------------------------|-----|------------------|------------------|---------------------------------|-------------|-----|-----|-------------------|------|
| <b>Speyer,<br/>1992<sup>103</sup></b> | RCT | United<br>States | Breast<br>cancer | 5-fluorouracil,<br>doxorubicin, | Dexrazoxane | Yes | N/A | No<br>information | None |
|---------------------------------------|-----|------------------|------------------|---------------------------------|-------------|-----|-----|-------------------|------|

---

|  |     |                  |  |                               |             |     |                                |   |      |
|--|-----|------------------|--|-------------------------------|-------------|-----|--------------------------------|---|------|
|  |     |                  |  | cyclophospha-<br>mide         |             |     |                                |   |      |
| <b>Venturini,<br/>1996<sup>104</sup></b> | RCT | Italy            | Breast<br>cancer                       | Epirubicin-<br>based therapy  | Dexrazoxane | Yes | N/A                            | No<br>information   | None |
| <b>Wexler,<br/>1996<sup>105</sup></b>    | RCT | United<br>States | Sarcoma                                | Doxorubicin-<br>based therapy | Dexrazoxane | No  | 37%<br>female                  | 76%<br>white, 12%<br>Black, 10%<br>Hispanic/<br>Latinx, 2%<br>Asian | None |
| <b>Swain,<br/>1997<sup>106</sup></b>     | RCT | United<br>States | Breast<br>cancer,<br>lung<br>carcinoma | Doxorubicin-<br>based therapy | Dexrazoxane | No  | 88%<br>female                  | 77% white,<br>15% Black,<br>8% other                                | None |
| <b>Lopez,<br/>1998<sup>107</sup></b>     | RCT | Italy            | Breast<br>cancer<br>and soft-          | Epirubicin-<br>based therapy  | Dexrazoxane | No  | 41%<br>female with<br>sarcoma; | No<br>information   | None |

|  |        |                  |                               |                                      |             |     |  |                                     |      |
|--|--------|------------------|-------------------------------|--------------------------------------|-------------|-----|--|-------------------------------------|------|
|  |        |                  | tissue<br>sarcoma             |                                      |             |     | N/A for<br>patients<br>with breast<br>cancer |                                     |      |
| <b>Lipshultz,<br/>2004<sup>108</sup></b> | RCT    | United<br>States | Acute<br>lymphoid<br>leukemia | Doxorubicin                          | Dexrazoxane | No  | 42%<br>female<br>patients                    | No<br>information                   | None |
| <b>Galetta,<br/>2005<sup>109</sup></b>   | RCT    | Italy            | NHL                           | Epirubicin-<br>based<br>chemotherapy | Dexrazoxane | No  | 45%<br>female                                | No<br>information                   | None |
| <b>Marty,<br/>2006<sup>110</sup></b>     | RCT    | France           | Breast<br>cancer              | Anthracycline<br>therapy             | Dexrazoxane | Yes | N/A  | 87% white,<br>7% Black,<br>2% other | None |
| <b>Sun, 2015<sup>111</sup></b>           | RCT    | China            | Breast<br>cancer              | Epirubicin-<br>based therapy         | Dexrazoxane | Yes | N/A  | No<br>information                   | None |
| <b>Tahover,<br/>2017<sup>112</sup></b>   | Cohort | Israel           | Breast<br>cancer              | Doxorubicin-<br>based therapy        | Dexrazoxane | No  | N/A  | No<br>information                   | None |



|                                    |        |               |  |                             |             |     |            |                |      |
|------------------------------------|--------|---------------|--|-----------------------------|-------------|-----|------------|----------------|------|
| <b>Kim, 2017<sup>113</sup></b>     | Cohort | Korea         | HER2 positive breast cancer                | Doxorubicin-based therapy   | Dexrazoxane | Yes | N/A        | No information | None |
| <b>Ganatra, 2019<sup>114</sup></b> | Cohort | United States | Breast, ovarian, HL, NHL, DLBCL, PTCL, AML | Anthracycline-based therapy | Dexrazoxane | No  | 50% female | No information | None |

AML=acute myeloid leukemia, CHOP=cyclophosphamide, doxorubicin, vincristine, prednisolone, CV=cardiovascular, CVD=cardiovascular disease, DLBCL=diffuse large B-cell lymphoma, HL=Hodgkin lymphoma, NHL=Non-Hodgkin lymphoma, PTCL=peripheral T-cell lymphoma  
 \*Cardiovascular risk factors include age, body mass index, diabetes, hypertension, dyslipidemia, history of smoking, family history of cardiac disease.

†Including angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and beta blockers.

‡Including any of the following: Anthracyclines, anti-metabolites, alkylating agents, vinca alkaloids, antitumor antibiotics.

References: 86-114